Bristol-Myers Squibb (BRM) Price & Analysis

Compare

18 Followers

BRM Stock Chart & Stats

€51.59

-€0.23(-0.42%)

At close: Jan 08 4:00 PM EST

€51.59

-€0.23(-0.42%)

Day’s Range― - ―

52-Week Range€36.60 - €58.20

Previous CloseN/A

Volume2.10K

Average Volume (3M)2.82K

Market Cap

€103.95B

Enterprise Value€68.13B

Total Cash (Recent Filing)€16.50B

Total Debt (Recent Filing)€51.04B

Price to Earnings (P/E)16.8

Beta0.49

Next Earnings

Apr 30, 2026

EPS Estimate

1.21

Next Dividend Ex-DateN/A

Dividend Yield5.01%

Share Statistics

EPS (TTM)1.06

Shares Outstanding2,035,753,000

10 Day Avg. Volume3,316

30 Day Avg. Volume2,822

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)7.02

Price to Sales (P/S)2.37

P/FCF Ratio8.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€50.32

Price Target Upside-2.46% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering20

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Eliquis Commercial ResilienceStronger-than-expected Eliquis sales and company guidance implying renewed growth challenge assumptions of imminent decline and could produce upside to revenue expectations.

Growth-product MomentumRobust commercial performance for growth-stage medicines such as Reblozyl, Camzyos, and Breyanzi produced revenue beats and signals expanding contributions from the new-product portfolio.

Late-stage Readouts Derisking PipelinePositive late-stage results from a competitor and encouraging safety signals for the company's anticoagulant candidate provide a favorable readthrough that reduces clinical risk and could lift investor confidence.

Bears Say

Generic Competition RiskUpcoming generic entrants for key medicines, including the leading anticoagulant, pose a clear threat to revenue and create pressure on future top-line growth.

Guidance Quality And Assumption RiskGuidance that depends on assumed pricing adjustments for the top product weakens the quality of reported beats and increases investor uncertainty until late-stage clinical results validate growth assumptions.

Legacy Portfolio UnderperformanceUnderperformance from several legacy products offset gains from newer launches and acted as a drag on overall reported results and profitability.

Bristol-Myers Squibb News

Bristol Myers price target raised to $40 from $37 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $40 from $37...

5d ago

BMY

Trump Trade: Argentina says U.S. to cut hundreds of tariffs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

5d ago

AZN

Bristol Myers price target raised to $68 from $64 at BofA

BofA raised the firm’s price target on Bristol Myers (BMY) to $68 from $64 and keeps a Buy...

5d ago

BMY

Bristol Myers price target raised to $72 from $62 at Guggenheim

Guggenheim raised the firm’s price target on Bristol Myers (BMY) to $72 from $62 and keeps a Buy...

6d ago

BMY

Bristol Myers price target raised to $64 from $60 at Citi

Citi raised the firm’s price target on Bristol Myers (BMY) to $64 from $60 and keeps a Neutral...

6d ago

BMY

Bristol Myers price target raised to $60 from $55 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Bristol Myers (BMY) to $60 from $55...

6d ago

BMY

Truist incrementally positive on Bristol Myers after Bayer asundexian data

Truist reiterated a Buy rating and $65 price target on Bristol Myers (BMY), saying the firm remains incrementally...

6d ago

BMY

TrumpRx website using technology from GoodRx, STAT says

President Trump is planning to announce the launch of his TrumpRx website, which uses technology from health care...

6d ago

AZN

BMY

Morning Movers: Ralph Lauren and Qualcomm sink after earnings

Futures have nudged downward in early action as investors assess the implications of Alphabet’s earnings and spending plans...

6d ago

Bristol Myers sees 2026 WW revenue growth of Eliquis 10%-15%

07:16 EST Bristol Myers (BMY) sees 2026 WW revenue growth of Eliquis 10%-15% Published first on TheFly –...

7d ago

BMY

Options Volatility and Implied Earnings Moves Today, February 05, 2026

Today, several major companies are expected to report earnings: Amazon (AMZN), Barrick Mining (B), Bristol-Myers Squibb (BMY), Conocophillips...

7d ago

BMY

These Are the Stocks Reporting Earnings Today – February 5, 2026

Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly...

7d ago

BMY

Options Volatility and Implied Earnings Moves This Week, February 02 – February 06, 2026

This week, several major companies will be reporting earnings. Among them are Amazon (AMZN), Alphabet Class A (GOOGL),...

10d ago

ACB

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow...

11d ago

BRM FAQ

What was Bristol-Myers Squibb Company’s price range in the past 12 months?

Bristol-Myers Squibb Company lowest stock price was €36.60 and its highest was €58.20 in the past 12 months.

What is Bristol-Myers Squibb Company’s market cap?

Bristol-Myers Squibb Company’s market cap is €103.95B.

When is Bristol-Myers Squibb Company’s upcoming earnings report date?

Bristol-Myers Squibb Company’s upcoming earnings report date is Apr 30, 2026 which is in 77 days.

How were Bristol-Myers Squibb Company’s earnings last quarter?

Bristol-Myers Squibb Company released its earnings results on Feb 05, 2026. The company reported €1.059 earnings per share for the quarter, beating the consensus estimate of €1.03 by €0.029.

Is Bristol-Myers Squibb Company overvalued?

According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bristol-Myers Squibb Company pay dividends?

Bristol-Myers Squibb Company pays a Quarterly dividend of €0.528 which represents an annual dividend yield of 5.01%. See more information on Bristol-Myers Squibb Company dividends here

What is Bristol-Myers Squibb Company’s EPS estimate?

Bristol-Myers Squibb Company’s EPS estimate is 1.21.

How many shares outstanding does Bristol-Myers Squibb Company have?

Bristol-Myers Squibb Company has 2,035,753,000 shares outstanding.

What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?

Bristol-Myers Squibb Company reported an EPS of €1.059 in its last earnings report, beating expectations of €1.03. Following the earnings report the stock price went up 4.011%.

Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?

Currently, no hedge funds are holding shares in DE:BRM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bristol-Myers Squibb Stock Smart Score

Outperform

Company Description

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Bristol-Myers Squibb (BRM) Earnings & Revenues

Historic Earnings Reports

BRM Company Deck

BRM Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all DE:BRM earnings summaries

BRM Revenue Breakdown

46.71% Growth Portfolio

53.29% Legacy Portfolio

BRM Stock 12 Month Forecast

Average Price Target

€50.32

▼(-2.46% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"€32","61":"€61","39.25":"€39.3","46.5":"€46.5","53.75":"€53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60.49871136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.3231642132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€50.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.6103952,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,39.25,46.5,53.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,48.056823950769235,49.09364790153847,50.13047185230769,51.167295803076925,52.20411975384616,53.24094370461539,54.27776765538462,55.31459160615385,56.35141555692308,57.38823950769231,58.42506345846154,59.46188740923077,{"y":60.49871136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,47.27408955486154,47.52817910972308,47.78226866458462,48.03635821944616,48.290447774307694,48.54453732916923,48.798626884030774,49.05271643889231,49.30680599375385,49.560895548615385,49.81498510347693,50.069074658338465,{"y":50.3231642132,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,45.98849193846154,44.95698387692308,43.925475815384615,42.893967753846155,41.862459692307695,40.830951630769235,39.799443569230775,38.76793550769231,37.73642744615385,36.70491938461539,35.67341132307692,34.64190326153846,{"y":33.6103952,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.695,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.778,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.238,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.834,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.404,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.599,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.489,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.881,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.458,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >